- Vertex Pharmaceuticals Inc.
- Genentech Inc.
- Pfizer Inc.
- Takeda Oncology
- GlaxoSmithKline PLC
- Cor Therapeutics Inc.
- Merck & Co. Inc.
- Aventis SA
- Eli Lilly & Co.
- Merck Serono SA
- Taisho Pharmaceutical Co. Ltd.
- Novartis AG
- Amgen Inc.
- Agouron Pharmaceuticals Inc.
- Vertex Pharmaceuticals LLC
- Gilead Sciences Inc.
- NeXstar Pharmaceuticals Inc.
- Millennium acquires Cor Therapeutics for $1.8bn
- Wellcome licenses Vertex HIV protease inhibitors
- Hoechst, Vertex expand ICE alliance
- Lilly, Vertex research hepatitis C drugs
- Serono licenses Vertex's caspase inhibitors
- Taisho, Vertex develop caspase inhibitors
- Novartis, Vertex in kinase protein deal
- Vertex acquires Aurora for $570mm
- Gilead acquires NeXstar for $550mm in all-stock deal
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.